Q3 2025 OraSure Technologies Inc Earnings Call Transcript
Key Points
- OraSure Technologies Inc (OSUR) reported total revenue of $27.1 million for Q3 2025, with core revenue at $27.0 million, indicating a stable performance despite market challenges.
- The company is expanding its product portfolio and customer relationships, aiming for profitable growth through investments in internal R&D, acquisitions, and partnerships.
- OraSure Technologies Inc (OSUR) signed a definitive agreement to acquire BioMedomics, enhancing its diagnostic portfolio with the Sickle SCAN test for sickle cell disease, which has strong market potential in underserved regions.
- The company is seeing traction with its syndemic approach in the US Diagnostics business, expanding its customer base in nonpublic health markets such as urgent care and hospital emergency rooms.
- OraSure Technologies Inc (OSUR) maintains a strong balance sheet with zero debt and $216 million in cash and cash equivalents, allowing for strategic investments and share repurchases.
- Revenue from the International Diagnostics business is expected to decline by approximately 20% in 2025 compared to 2024, due to slower orders for HIV tests and changes in the funding environment.
- The US Diagnostics business is projected to experience a low single-digit percentage decline in revenue for the full year 2025 compared to 2024.
- The Sample Management business anticipates a sequential revenue decline in Q4 2025, consistent with typical seasonal ordering patterns.
- OraSure Technologies Inc (OSUR) reported a GAAP operating loss of $16.1 million and a non-GAAP operating loss of $12.7 million for Q3 2025.
- The company expects continued disruption in ordering patterns from a major consumer genetics customer, impacting revenue in Q4 2025.
Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the OraSure Technologies Inc 2025 third-quarter earnings conference call. (Operator Instructions)
I would now like to turn the conference over to Jason Plagman, VP of Investor Relations. You may begin.
Good afternoon, and welcome to OraSure Technologies third quarter 2025 earnings call. Participating in the call today for OTI are Carrie Eglinton Manner, our President and Chief Executive Officer; and Ken McGrath, our Chief Financial Officer.
As a reminder, today's webcast is being recorded, and the recording can be found on our Investor Relations website. Before we begin, you should know that this call may contain certain forward-looking statements, including statements with respect to revenues, expenses, profitability, earnings or loss per share and other financial performance, product development, shipments and markets, business plans, regulatory filings and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
